ArticleJournal of the National Comprehensive Cancer Network : JNCCN2016
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 224 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
224 citing papers in PubMed, 5 syntheses or guidelines pooled it, 735 citations in OpenAlex.
- Pooled it
- Pooled it
- A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC.Medicine · 2020Pooled it
- Pharmacogenetic Association betweenBioMed research international · 2020Pooled it
- PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.Scientific reports · 2017Pooled it
- A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.Journal for immunotherapy of cancer · 2018Trial
- A novel technique for tumor localization and targeted lymphatic mapping in early-stage lung cancer.The Journal of thoracic and cardiovascular surgery · 2017Trial
- Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells.Respiratory research · 2017Trial
- Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Trial
- Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- iRGD-modified co-loaded curcumin piperine liposomes inhibit angiogenesis in non-small cell lung cancer through the VEGFR2/P38/MK2 signaling axis.Discover oncology · 2025Article
- IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer.Future oncology (London, England) · 2025Article
- Geographic Access to Cancer Care and Treatment and Outcomes of Early-Stage Non-Small Cell Lung Cancer.JAMA network open · 2025Article
- Evaluation of the efficacy and safety of durvalumab combined with chemotherapy, radiotherapy, or other agents in advanced non-small cell lung cancer: a meta-analysis.International journal of clinical and experimental pathology · 2025Review
- Microsomal glutathione transferase 1 confers cisplatin resistance of non-small cell lung cancer via interaction with arachidonate lipoxygenase 5 to repress ferroptosis.Iranian journal of basic medical sciences · 2025Article
- Clinico-pathological characteristics and treatment outcome in non-small cell lung cancer in Greenland 2015-2020 - a comparison with the cohort from 2004 to 2010.Acta oncologica (Stockholm, Sweden) · 2024Article
- Nomograms predicting benefit after immunotherapy in oral bifidobacteria supplementation ICC patients: a retrospective study.BMC cancer · 2024Article
- Establishment and verification of novel TNM staging system for lung mucinous adenocarcinoma.BMC cancer · 2024Article
- Preparing for the unexpected: Recommendations for returning secondary findings in late-stage cancer care.Genetics in medicine : official journal of the American College of Medical Genetics · 2024Article
- Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma.Frontiers in immunology · 2024Article
164 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 20 institutions in 7 countries.
Funding
Abstract
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.